Publications

ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for 1 Pancreatic Ductal Adenocarcinoma

Download PDF
Resource: ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for 1 Pancreatic Ductal Adenocarcinoma

.

Related Articles

Reversible Downregulation of HLA Class I in Adenoid Cystic Carcinoma

Link
Glioblastoma Phagocytic Cell Death: Balancing the Opportunities for Therapeutic Manipulation

Link